SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection

SCHISTOACT: a protocol for an open-label, five-arm, non-inferiority, individually randomized controlled trial of the efficacy and safety of praziquantel plus artemisinin-based combinations in the treatment of Schistosoma mansoni infection

Abstract Background Schistosomiasis control relies on praziquantel for preventive chemotherapy. Alternative drugs are needed for the treatment and control of schistosomiasis. Praziquantel is effective against adult schistosome worms but ineffective against larval stages of the parasite and cannot pr...

Full description

Bibliographic Details
Main Authors: Charles O. Obonyo, Vincent O. Were, Peter Wamae, Erick M. O. Muok
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Trials
Subjects:
Schistosomiasis
Artemisinin
Praziquantel
Combinations
Children
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-023-07790-3

Internet

https://doi.org/10.1186/s13063-023-07790-3

Similar Items